BrightGene Bio-Medical Technology Co Ltd, an innovative pharmaceutical company in SIP, recently blazed a trail for financing of private tech companies by issuing a sci-tech innovation bond in the country’s interbank bond market.

BrightGene is engaged in developing a variety of products including those for treatment of metabolic disorders, respiratory diseases and autoimmune diseases, with several products now competing globally.

The three-year bond, the first of its kind by an innovative drugmaker in the market, is priced at RMB200 million, with a coupon rate of 3.19%. The fund raised will be used to support clinical trials for key drug candidates, upgrading of technology platforms and development of novel products.

It is worth mentioning that a Credit Risk Mitigation Warranty was issued at the same time to protect buyers from the default risk of the underlying bond. This is expected to help significantly accelerate the financing efficiency of the company.

October 23, 2025